Insider Selling: Fennec Pharmaceuticals (TSE:FRX) Insider Sells C$10,350,000.00 in Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) insider Southpoint Capital Advisors Lp sold 1,000,000 shares of the company’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of C$10.35, for a total transaction of C$10,350,000.00. Following the transaction, the insider owned 2,744,741 shares of the company’s stock, valued at C$28,408,069.35. This represents a 26.70% decrease in their position.

Southpoint Capital Advisors Lp also recently made the following trade(s):

• On Friday, November 14th, Southpoint Capital Advisors Lp sold 160,100 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$11.24, for a total transaction of C$1,799,524.00.
• On Monday, November 17th, Southpoint Capital Advisors Lp sold 85,918 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$12.35, for a total transaction of C$1,061,087.30.

Fennec Pharmaceuticals Price Performance

TSE FRX opened at C$10.56 on Tuesday. The company has a 50-day moving average price of C$10.72 and a two-hundred day moving average price of C$11.54. Fennec Pharmaceuticals Inc. has a 52 week low of C$7.02 and a 52 week high of C$13.83. The stock has a market cap of C$360.66 million, a price-to-earnings ratio of -40.62 and a beta of 2.78. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.